![BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE)](/upload/1124/V69883.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
Opioid Receptor[1]
|
|---|---|
| ln Vitro |
In SH-SY5Y cells, BW-180C ([D-Ala2, D-Leu5]-Enkephalin) dramatically decreases cellular transcription without endangering the cells. After primary neurons recover for 72 hours in the absence of BW-180C, transcriptional activity fully resumes[1].
|
| ln Vivo |
BW-180C ([D-Ala2, D-Leu5]-Enkephalin) defends against IR damage in hepatocytes but not in rat liver sinusoidal endothelial cells. Although the BW-180C group's GPT levels are much lower than the Control group's, the two groups' serum HA levels are the same. In comparison to the Control group, the BW-180C group's liver tissue MDA concentrations are noticeably lower[2]. The activation of both mu- and delta-opioid receptors mediates the analgesia brought on by BW-180C (DADLE)[3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Human neuroblastoma cells, SH-SY5Y cells Tested Concentrations: 100 pM to 10 μM Incubation Duration: 24-72 hrs (hours) Experimental Results: Dramatically inhibited cellular transcription. Western Blot Analysis[1] Cell Types: Primary Cortical neurons Tested Concentrations: 100 nM Incubation Duration: 72 hrs (hours) Experimental Results: Treatment Dramatically diminished phosphorylation of RNA polymerase II at both Ser 2 and Ser 5. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats weighing 200 to 250 g[2]
Doses: 5 mg/kg Route of Administration: Administered intravenously (iv) into the inferior vena cava Experimental Results: After 120 min of reperfusion, the serum GPT levels were Dramatically lower in the DADLE group than in the Control group. Animal/Disease Models: Male C57BL/6 mice (age, 35-42 days; weight, 18-22 g; 6 mice in each group)[3] Doses: 5 mg/kg Route of Administration: Injected intraperitoneally (ip) 15 min prior to I/R Experimental Results: The serum levels of AST and ALT in the serum DADLE group were Dramatically lower. |
| References |
|
| Additional Infomation |
A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.
A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate. |
| Molecular Formula |
C29H39N5O7
|
|---|---|
| Molecular Weight |
569.65
|
| Exact Mass |
569.285
|
| CAS # |
63631-40-3
|
| PubChem CID |
6917707
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.489
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
41
|
| Complexity |
885
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
|
| InChi Key |
ZHUJMSMQIPIPTF-IBURTVSXSA-N
|
| InChi Code |
InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1
|
| Chemical Name |
(2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (438.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7555 mL | 8.7773 mL | 17.5546 mL | |
| 5 mM | 0.3511 mL | 1.7555 mL | 3.5109 mL | |
| 10 mM | 0.1755 mL | 0.8777 mL | 1.7555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
